Smartleaf Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Smartleaf Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.5K	Hold	589	–	–	﹤0.01%	2054
2026 Q1	$14K	Sell	589 -1,175	-67%	-$28K	﹤0.01%	2151
2025 Q4	$41.1K	Buy	1,764 +630	+56%	+$14K	﹤0.01%	1649
2025 Q3	$22.2K	Buy	1,134 +111	+11%	+$2.28K	﹤0.01%	1779
2025 Q2	$22.3K	Buy	1,023 +246	+32%	+$5.81K	﹤0.01%	1504
2025 Q1	$19.2K	Sell	777 -68	-8%	-$1.53K	﹤0.01%	1623
2024 Q4	$17.8K	Buy	845 +559	+195%	+$12K	﹤0.01%	1711
2024 Q3	$5.59K	Buy	286 +57	+25%	+$1.06K	﹤0.01%	2072
2024 Q2	$3.44K	Buy	+229	New	+$3.56K	﹤0.01%	1985

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Smartleaf Asset Management's CPRX Position: Q2 2026 in Review

Smartleaf Asset Management held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 589 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

Smartleaf Asset Management first reported a position in CPRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $41.1K in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Smartleaf Asset Management held 589 shares of Catalyst Pharmaceutical worth $18.5K as of Q2 2026.
Smartleaf Asset Management left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2054 holding.
Smartleaf Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 9 quarters since.
Smartleaf Asset Management's Catalyst Pharmaceutical position peaked at $41.1K in Q4 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.